BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 101
- Registration Number
- NCT05407675
- Locations
- 🇺🇸
Local Institution - 0010, Boston, Massachusetts, United States
🇺🇸Local Institution - 0001, Hackensack, New Jersey, United States
🇺🇸Local Institution - 0003, Houston, Texas, United States
A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT05405543
- Locations
- 🇺🇸
Local Institution - 0001, Anaheim, California, United States
A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT05389722
- Locations
- 🇺🇸
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States
A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 380
- Registration Number
- NCT05382715
- Locations
- 🇩🇪
Local Institution - 0001, Berlin, Germany
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 220
- Registration Number
- NCT05372354
- Locations
- 🇨🇦
University Health Network UHN - Princess Margaret Hospital PMH, Toronto, Ontario, Canada
🇺🇸John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 415
- Registration Number
- NCT05369832
- Locations
- 🇺🇸
Local Institution - 0048, Dothan, Alabama, United States
🇺🇸Local Institution - 0206, Chandler, Arizona, United States
🇺🇸Local Institution - 0216, Gilbert, Arizona, United States
A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 158
- Registration Number
- NCT05362045
- Locations
- 🇺🇸
Clinical pharmacology of Miami, Miami, Florida, United States
🇺🇸Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸Ppd Phase I Clinic, Austin, Texas, United States
A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy Participants
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT05350800
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 162
- Registration Number
- NCT05337137
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇫🇷CHU de Reims-Hopital Robert Debre, Reims, France
🇭🇰The Chinese University of Hong Kong Prince of Wales Hospital, Shatin, Hong Kong
A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 104
- Registration Number
- NCT05337345
- Locations
- 🇺🇸
Anaheim Clinical Trials Llc, Anaheim, California, United States